CEL-SCI Corp (CVM)
1.515
+0.02
(+1.00%)
USD |
NYAM |
Apr 19, 14:53
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 81.78M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -39.02% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 6.465 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 96.13% |
Profile
| CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia. |
| URL | https://www.cel-sci.com |
| Investor Relations URL | https://cel-sci.com/new-investor-information/ |
| HQ State/Province | Virginia |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 13, 2024 (est.) |
| Last Earnings Release | Feb. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 28, 1996 |
Ratings
Profile
| CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia. |
| URL | https://www.cel-sci.com |
| Investor Relations URL | https://cel-sci.com/new-investor-information/ |
| HQ State/Province | Virginia |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 13, 2024 (est.) |
| Last Earnings Release | Feb. 15, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 28, 1996 |